FDA Requires Vision Warnings on GLP-1 Medications

US health regulators are ordering manufacturers of GLP-1 receptor agonist medications to update product labels with warnings about a rare eye condition. The condition, known as non-arteritic anterior ischemic optic neuropathy, can trigger sudden and permanent vision impairment in one eye.

The regulatory action follows an agency review of clinical trials and real-world data. An analysis of 126 clinical trials involving over 134,000 participants recorded a higher incidence of the condition among patients using GLP-1 drugs compared to those taking placebos or alternative blood sugar treatments.

Despite the label updates, a manufacturer of the medications stated that the available data do not establish a direct cause-and-effect relationship, expressing confidence in the overall benefit-risk profile of the drugs. Authorities have advised patients experiencing sudden vision changes to seek immediate medical evaluation.